{"id":390337,"date":"2019-10-31T00:00:00","date_gmt":"2019-10-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2019-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-03-31T10:46:10","modified_gmt":"2026-03-31T10:46:10","slug":"dlsfcg0004-2019-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2019-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The maturing yet highly lucrative market for multiple sclerosis (<abbr title=\"multiple sclerosis\">MS<\/abbr>) disease-modifying therapies (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s) will continue to fragment as new entrants further shift the complicated treatment algorithm. Roche \/ Genentech\u2019s Ocrevus, Merck Serono\u2019s Mavenclad, and a growing array of next-generation compounds from Novartis, Celgene, Actelion\/Janssen, Biogen, Genmab, and\u00a0TG\u00a0Therapeutics will intensify competition in the saturated relapsing\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0market. Meanwhile, Ocrevus continues to transform treatment in the <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854611960821093348687\">underserved<\/gwmw>\u00a0<abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>\u00a0population, and developers like MediciNova (with its intriguing candidate <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854611960822810391083\">ibudilast<\/gwmw>) and Biogen (<gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854611960823747017401\">opicinumab<\/gwmw>) have renewed their focus on developing <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854611960829599747573\">neuroprotective<\/gwmw> or <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854611960829431455560\">reparative<\/gwmw> treatments in\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u2014now the \u201cnext frontier\u201d in a market replete with reliable anti-inflammatory options. Separately, the looming entry of oral generics will introduce a new variable in this high-cost market as <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854611975173711064312\">reimbursement authorities race<\/gwmw> to rein in <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854611975172391084126\">healthcare<\/gwmw> costs. Understanding these intersecting forces will be key to the success of current and future players in this evolving market.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>\u00a0What is the commercial outlook for Ocrevus, Mavenclad, next-generation <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854611997468542997735\">fumarates<\/gwmw>, and S1P receptor modulators in the competitive relapsing MS space, and where will they fit into an evolving treatment algorithm?<\/li>\n<li>What impact will Ocrevus and <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854612003639498282044\">ibudilast<\/gwmw> have in the progressive\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0market?<\/li>\n<li>What clinical roles will <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854612021063734714096\">entrenched<\/gwmw> platform <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854612021065506705138\">injectables<\/gwmw>, current and next-generation orals, and\u00a0<gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854612021066293931540\"><abbr title=\"monoclonal antibody\">MAb<\/abbr>s<\/gwmw> play in the evolving\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0treatment algorithm?<\/li>\n<li>How will generic competition shape the\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0market?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research:<\/strong>\u00a0Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other\u00a0<abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0research.<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Diagnosed prevalence of\u00a0<abbr title=\"multiple sclerosis\">MS<\/abbr>\u00a0by country, segmented by\u00a0<abbr title=\"clinically isolated syndrome\">CIS<\/abbr>,\u00a0<abbr title=\"relapsing-remitting multiple sclerosis\">RR-MS<\/abbr>,\u00a0<abbr title=\"secondary-progressive multiple sclerosis\">SP-MS<\/abbr>, and\u00a0<abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>; drug-treated cases.<\/p>\n<p><strong>Emerging therapies:<\/strong>\u00a0Phase II: 9 drugs; Phase III\/preregistration: 10 drugs; coverage of select Phase I products.<\/p>\n<p><strong>Market forecast features:\u00a0<\/strong>Patient-based market forecast extending through 2028, segmented by brands\/generics.<\/p>\n<p><strong>Product Description:<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast\u00a0<\/em>provides <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854612082193400560740\">comprehensive market intelligence<\/gwmw> with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390337","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390337\/revisions"}],"predecessor-version":[{"id":576593,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390337\/revisions\/576593"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}